Adia Nutrition Stock Price, News & Analysis

Adia Nutrition (OTC Pink: ADIA) has appointed a PCAOB accounting firm for a comprehensive third-party audit as part of its strategy to uplist from OTC Pink Sheets to the OTCQB Venture Market. This move aims to enhance visibility and attract more investors while demonstrating the company's commitment to transparency.

The uplisting to OTCQB is expected to provide several benefits, including increased transparency through higher reporting standards, greater market liquidity, enhanced investor confidence, and broader accessibility to investors. The company has outlined a roadmap to eventually list on the Nasdaq Small Cap, which involves completing the OTCQB uplisting, establishing SEC reporting, scaling operations to meet Nasdaq's standards, and ensuring adequate shareholder equity and public float.

Adia Nutrition (OTC Pink: ADIA) has entered the $15.1 billion global stem cell market through its medical division, Adia Med, with the opening of its first clinic in Winter Park, Florida. The facility offers stem cell treatments using FDA-compliant 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps).

The company aims to provide treatments comparable to international locations like Panama, Mexico, Brazil, and Switzerland, but with the advantage of U.S.-based care. The clinic utilizes umbilical cord stem cells and focuses on treating conditions including inflammation, autoimmune conditions, and orthopedic issues.

Key advantages include quality stem cells from ethical sources, domestic convenience eliminating international travel, and operations under U.S. FDA health regulations emphasizing safety and transparency.

Adia Nutrition has unveiled an exclusive artwork by performance artist Rock Demarco at its clinic in Winter Park, Florida. The piece, featuring butterflies and stem cells, symbolizes transformation and healing through regenerative therapies. The artwork installation coincides with the announcement that the clinic has doubled its scheduled treatments for early January due to high demand.

Former WWE superstar Jeff Sciullo attended the unveiling ceremony, showing support for regenerative medicine and the MS community. The artwork will serve as an inspirational symbol for patients seeking treatments like Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for multiple sclerosis and other regenerative therapies for muscle injuries, joints, ligaments, and tendons.

Adia Nutrition has launched its first clinic in Winter Park, Florida, marking a significant expansion in regenerative medicine services. The new facility specializes in Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis patients and offers various regenerative therapies including stem cell treatments and platelet-rich plasma (PRP) procedures. The state-of-the-art clinic, strategically located in Winter Park, is now open and accepting patients, providing a dedicated environment for advanced medical treatments.

ADIA Nutrition (OTC Pink: ADIA) announced its partner Jeff Sciullo (WWE's Elias) will compete at WrestleCade SuperShow 2024. More importantly, the company's medical division, ADIA Med, is preparing to open an Autologous Hematopoietic Stem Cell Transplantation (AHSCT) clinic for Multiple Sclerosis by Christmas in Winter Park, Florida. The facility will offer experimental treatments using umbilical cord stem cells. Additionally, ADIA has established ADIA Labs to distribute umbilical cord stem cells to doctors and clinics nationwide, focusing on Mesenchymal Stem Cells (MSCs) for homologous use in regenerative medicine.

Adia Nutrition has secured a lease for its first medical clinic at Winter Park Medical Center, Florida. The fully built-out and recently remodeled facility will feature a rare stem cell extraction department and private IV rooms, specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis patients. The clinic is expected to be operational by year-end and begin accepting patients on January 1st, 2025. This strategic expansion represents the company's model for future nationwide clinic rollouts.

Adia Nutrition (OTC Pink: ADIA) has announced significant progress in its Multiple Sclerosis (MS) treatment initiative. The company has signed a Letter of Intent (LOI) to lease a clinic in Winter Park, Florida, which will offer Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for MS patients. This development is ahead of the company's initial expansion projections.

To ensure regulatory compliance, Adia Nutrition has engaged the law firm Smith Hulsey & Busey, with attorney Jeanne Helton leading efforts to secure necessary medical licenses and uphold patient care standards. The Winter Park clinic will feature state-of-the-art facilities, representing a significant step forward in personalized healthcare for MS treatment.

ADIA Nutrition (OTC Pink: ADIA) has announced the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh Barot, MD, an oncologist from the Southwest Cancer Center. This unanimous decision by the Board, led by Dr. Monica Sher, MD, and Dr. Richard Edwards, DO, marks a significant milestone for the company. Dr. Barot will focus on overseeing ADIA's aHSCT (autologous hematopoietic stem cell transplantation) treatments for Multiple Sclerosis (MS) patients.

The appointment strengthens ADIA Nutrition's medical leadership and expertise in advancing healthcare solutions. Dr. Barot's extensive background in oncology is expected to be instrumental in refining aHSCT protocols and expanding treatment options for MS patients. With the medical board now complete, ADIA Nutrition is prepared to establish and refine all protocols and procedures for their aHSCT treatment for MS, aiming to make it a more accessible and effective option.

ADIA Nutrition Inc. (OTC Pink: ADIA) has made a strategic move to strengthen its intellectual property holdings by hiring a prominent Winter Springs law firm. The company aims to expand its trademark protection for its Biolete brand, including new registrations for "Biolete Coffee" and "Biolete Mushroom Coffee w/ Protein". This decision is driven by the rapid growth in the high-protein and mushroom-infused coffee markets, which are projected to reach $2.64 billion and $4.12 billion by 2029 and 2030, respectively.

CEO Larry Powalisz emphasized the importance of trademark protection in ADIA's strategy to become a market leader. The company is targeting the growing demand for health-conscious coffee alternatives, particularly those infused with adaptogenic mushrooms known for their cognitive and immune health benefits.